Haemonetics (NYSE:HAE) Given New $70.00 Price Target at Citigroup

Haemonetics (NYSE:HAE) had its price target lowered by Citigroup from $75.00 to $70.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a neutral rating on the medical instruments supplier’s stock.

A number of other analysts also recently weighed in on the stock. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. JPMorgan Chase & Co. lifted their price target on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $83.89.

Haemonetics Stock Down 3.4%

Shares of HAE opened at $60.69 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 1.31 and a beta of 0.28. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The business’s 50 day simple moving average is $67.49 and its 200-day simple moving average is $64.66.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. Haemonetics’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the firm posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities analysts expect that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP purchased a new stake in Haemonetics in the 1st quarter valued at about $216,000. United Services Automobile Association bought a new position in Haemonetics in the 1st quarter worth about $212,000. Empowered Funds LLC increased its position in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after acquiring an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.